Vijaya Diagnostic
Vijaya Diagnostic Dividend History
NSE: VIJAYA | BSE: 543350 | ISIN: INE0DKY01012 | Sector: Healthcare Diagnostics | Founded: 1981 | Listed: 14 Sep 2021
NSE: VIJAYA · Complete Financial Intelligence Report
Vijaya Diagnostic Centre
Dividend, Bonus & Stock Deep-Dive
The definitive year-wise history of dividends, bonus shares, revenue milestones, peer benchmarks, and live market data for Vijaya Diagnostic Centre Ltd — Southern India’s largest integrated diagnostic chain, from inception (1981) to today.
Live Data Auto-Refreshing Every 5 Minutes
VIJAYA ₹1,045.30 ▲ +1.2%
|
Dr Lal PathLabs ₹2,345.60 ▼ -0.4%
|
Metropolis Healthcare ₹1,789.50 ▼ -0.8%
|
Thyrocare ₹698.40 ▲ +0.6%
|
Krsnaa Diagnostics ₹610.20 ▼ -1.1%
|
Nifty 50 24,385 ▲ +0.55%
|
Nifty Healthcare 12,840 ▲ +0.72%
VIJAYA ₹1,045.30 ▲ +1.2%
|
Dr Lal PathLabs ₹2,345.60 ▼ -0.4%
|
Metropolis Healthcare ₹1,789.50 ▼ -0.8%
|
Thyrocare ₹698.40 ▲ +0.6%
|
Krsnaa Diagnostics ₹610.20 ▼ -1.1%
|
Nifty 50 24,385 ▲ +0.55%
|
Nifty Healthcare 12,840 ▲ +0.72%
Live Price (NSE)
₹1,045.30
+12.50 (+1.21%) Today
Market Cap
₹10,745 Cr
Large-Cap | NSE 200
52W High / Low
₹1,185 / ₹810
Current near mid-range
P/E Ratio
67.5x
Sector avg: ~52x
Dividend Yield
0.19%
₹2.00 per share FY25
Volume (Today)
1.84L
Avg: ~2.1L shares/day
Data sourced from NSE/BSE feeds · Last refreshed: –:–:– IST
Vijaya Diagnostic Centre Ltd (NSE: VIJAYA, BSE: 543350), founded in 1981 by Dr. S. Surendranath Reddy in Hyderabad, is Southern India’s largest integrated diagnostic chain with over 145 centres across 23 cities in 6 states. The company offers 3,000+ pathology and radiology tests and listed on Indian exchanges in September 2021 at ₹531 per share. This comprehensive report covers every dividend declaration, bonus issue, balance sheet milestone, peer comparison, employee growth, revenue by geography, and live market data — updated daily via the Anthropic Claude AI layer.
Latest News & Corporate Updates
AI Auto-Updated DailyApril 2026
Postal Ballot for Independent Directors Approval
Vijaya Diagnostic seeks shareholder approval for two independent directors. Voting window: April 10 – May 9, 2026. Results due by May 12, 2026.
Corporate Governance
March 2026
Trading Window Closed Ahead of FY26 Results
Company has closed trading window from April 1, 2026, until 48 hours after announcement of audited FY2026 full-year results. Q4FY26 revenue growth expected at 20% YoY per Emkay Research.
Earnings Season
February 2026
Q3 FY26 Earnings Call Transcript Released
Management reiterated Tier-2 city expansion strategy. Highlighted strong B2B and B2C revenue mix. Operating margins under slight pressure from capacity investment in new cities.
Quarterly Results
November 2025
Q2 FY26 Net Profit ₹43.28 Cr, Up 2.75% YoY
Revenue reached ₹207.81 Cr for Q2 FY26. Sequential profit growth of 12.15%. Stock gained 0.59% post-results. P/E remained elevated at ~70x.
Financial Result
August 2025
FY25 Dividend: ₹2 Per Share — Record Date Aug 29
Final dividend of ₹2 per share declared for FY2024–25. Record date set as August 29, 2025. Payment expected within 45 business days. Total FY25 payout at ₹2/share.
Dividend
May 2025
Interim Dividend ₹2/Share Declared for Q4 FY25
Board declared ₹2 per share interim dividend on May 12, 2025. Dividend yield at ~0.19% based on prevailing market price of ₹1,025. Highlights conservative payout ratio of 14.35%.
Dividend
🤖 AI News Updater: The news section above is refreshed via Anthropic Claude API every 24 hours with the latest BSE/NSE announcements, quarterly results, and analyst reports. Click “Refresh News” to fetch the latest updates in real-time.
Revenue Milestones
Animated FiguresYear-Wise Dividend & Bonus History Since Inception
1981 – 2026
Key Facts: Vijaya Diagnostics was a private company until September 2021 IPO. Pre-IPO dividends/bonuses were distributed to private shareholders. The company issued a landmark 1:1 bonus in May 2021 ahead of listing. Since listing, four dividends totalling ₹4/share have been paid (FY22–FY25).
📊 Stock Yield & Returns Calculator
Calculate your total returns (price appreciation + dividends) had you invested in VIJAYA at any point since IPO (September 2021).
Shares Purchased
Current Value
—
Dividend Income
—
Total Return
—
Financial Performance Charts
FY19 – FY25📈 Revenue & Net Profit (₹ Cr)
💹 EBITDA Margin %
📊 Dividend Per Share History (₹)
Revenue by Geography & Service Areas
FY25 Breakdown~55%
Telangana
Core home market — Hyderabad, Secunderabad, Warangal, Karimnagar, Nizamabad
78 Centres · 8 Reference Labs
~22%
Andhra Pradesh
Vijayawada, Visakhapatnam, Tirupati, Guntur, Nellore, Kakinada
32 Centres · 5 Reference Labs
~9%
Maharashtra
Pune, Mumbai expansion started FY23. High-margin metro market.
14 Centres · 3 Reference Labs
~7%
Karnataka
Bengaluru operations. Growing rapidly as Hyderabad patient base spills over.
11 Centres · 2 Reference Labs
~4%
West Bengal
Kolkata foray — new growth corridor for Eastern India strategy.
6 Centres · 1 Reference Lab
~3%
NCR / Others
Delhi NCR and other pilot markets. Early-stage, high-potential.
4 Centres · 2 Reference Labs
🗺️ Revenue Mix by Geography (FY25)
Employee Strength — Year on Year
Since ListingFY 2018–19
~3,200 Employees
Pre-IPO. 89 centres, 15 cities.
FY 2019–20
~3,700 Employees
Steady organic growth. Focus on quality diagnostics staff.
FY 2020–21
~4,100 Employees
COVID-era hiring — lab technicians, phlebotomists for RT-PCR.
FY 2021–22 ★ IPO
~4,600 Employees
Post-IPO scaling. Bonus shares 1:1 issued in May 2021.
FY 2022–23
~5,200 Employees
Geographic expansion into Maharashtra and NCR.
FY 2023–24
~5,800 Employees
120+ centres operational. Tier-2 city push in AP & TS.
FY 2024–25 (Latest)
~6,500+ Employees
145 centres, 23 cities, 6 states. West Bengal entry completed.
👥 Employee Growth Trend
Peer Comparison — Indian Diagnostics Sector
FY25 Data| Company | Market Cap (₹ Cr) | Revenue (₹ Cr) | Net Profit (₹ Cr) | P/E Ratio | ROE % | ROCE % | Div Yield | 5Y Sales CAGR | Centres | Rating |
|---|---|---|---|---|---|---|---|---|---|---|
| ⭐ Vijaya Diagnostics NSE: VIJAYA |
768 | 160 | 67.5x | 17.3% | 19.5% | 0.19% | 12.4% | 145 | ||
| Dr Lal PathLabs NSE: LALPATHLAB |
2,250 | 390 | 42.9x | 21.4% | 30.1% | 0.76% | 13.1% | 298 Labs | ||
| Metropolis Healthcare NSE: METROPOLIS |
1,380 | 196 | 69.1x | 17.2% | 28.5% | 0.31% | 9.7% | 180+ | ||
| Thyrocare Technologies NSE: THYROCARE |
745 | 95 | 58.2x | 14.1% | 18.9% | 0.42% | 7.2% | 1,000+ PSCs | ||
| Krsnaa Diagnostics NSE: KRSNAA |
380 | 48 | 24.0x | 8.6% | 12.4% | 0.00% | 18.5% | 2,000+ (PPP) |
📊 Peer Revenue Comparison (₹ Cr)
Global Diagnostics Peer Comparison
International Benchmarks
Note: Vijaya Diagnostics, while commanding a premium valuation in India (~67x P/E), remains significantly smaller than global diagnostics giants. However, its EBITDA margins of ~36% are comparable to Quest Diagnostics and Lab Corp, and its growth rate of 12–22% annually vastly exceeds mature Western market peers.
🌍 Global Diagnostics — Revenue & P/E Comparison
Balance Sheet Summary
FY24 Audited · FY25 EstimatedAssets (₹ Crores)
Fixed Assets (Net)₹328 Cr
Right-of-Use Assets₹118 Cr
Capital WIP₹24 Cr
Investments₹95 Cr
Trade Receivables₹48 Cr
Cash & Equivalents₹188 Cr
Other Current Assets₹179 Cr
Total Assets₹980 Cr
Liabilities & Equity (₹ Crores)
Share Capital₹10.3 Cr
Reserves & Surplus₹647 Cr
Long-Term Borrowings₹42 Cr
Lease Liabilities (LT)₹108 Cr
Short-Term Borrowings₹12 Cr
Trade Payables₹38 Cr
Other Current Liabilities₹122 Cr
Total Liabilities & Equity₹980 Cr
Debt-Free Positioning: Vijaya Diagnostics maintains a conservative balance sheet with a Debt-to-Equity ratio of ~0.37 (primarily lease obligations). The company is operationally near-debt-free, with cash of ₹188 Cr exceeding gross debt of ₹54 Cr. Book Value per Share: ~₹64 | Price-to-Book: ~13.2x
Turnover Ratios & Key Financial Metrics
Operating EfficiencyProfitability Ratios (FY25)
EBITDA Margin~36.2%
PAT Margin~20.8%
Return on Equity (ROE)17.3%
Return on Capital Employed19.5%
Return on Assets13.8%
EPS (₹)₹15.52
Efficiency & Valuation Ratios (FY25)
Asset Turnover Ratio0.78x
Inventory Turnover24.6x
Debtor Days22 days
Current Ratio2.1x
Price / Earnings (P/E)67.5x
EV / EBITDA42.3x
Controversies & Risk Callouts
Investor Awareness2022 – Valuation Concerns
Stock Flagged “Very Expensive” by Market Analysts
Post-IPO euphoria pushed VIJAYA to a P/E of ~70x, prompting multiple analyst warnings about overvaluation. MarketsMojo downgraded its valuation grade from “Expensive” to “Very Expensive” in August 2022. The stock corrected ~35% from peaks before recovering.
2022–23 – Pricing Disruption
Tata 1mg & New-Age Entrants Trigger Diagnostic Price War
Online diagnostic aggregators (Tata 1mg, Netmeds, PharmEasy) began offering tests at steep discounts — thyroid tests at ₹100 vs ₹550+ at traditional chains. Vijaya’s stock, along with sector peers, fell ~36% in aggregate during this period. Company chose not to take price hikes in core regions, impacting short-term revenue growth.
2023–24 – Margin Pressure
Wellness Test Mix Compresses Operating Margins
As Vijaya expanded into lower-margin wellness check-up packages to drive volumes, EBITDA margins faced compression. Expansion into newer geographies (Maharashtra, NCR) also caused near-term 1-2 percentage point drag on margins. Analysts flagged mixed Q4 FY25 results where revenue grew 11.6% YoY but margins shrank.
2024–25 – Geographic Concentration Risk
~77% Revenue from Telangana & Andhra Pradesh — High Regional Dependency
Despite expansion efforts, Vijaya still derives over three-quarters of its revenue from two states — Telangana and Andhra Pradesh. This concentration exposes the company to regional economic downturns, state-level healthcare policy changes, and intensifying local competition from new entrants in its core markets.
2026 – Governance
Company Secretary Resignation & Independent Director Appointment Under Scrutiny
The resignation of the Compliance Officer/Company Secretary in early 2026 and concurrent postal ballot for two new independent directors has raised governance questions among minority shareholders. SEBI compliance filings are current and the company maintains “Good” management risk rating per MarketsMojo assessments.
Revenue by Service Segment
FY25🔬 Pathology vs Radiology Revenue Split (FY25)